Ardelyx (FRA:41X) ROCE % : 13.20% (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Ardelyx ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Ardelyx's annualized ROCE % for the quarter that ended in Dec. 2024 was 13.20%.

Ardelyx ROCE % Historical Data

The historical data trend for Ardelyx's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ardelyx ROCE % Chart

Ardelyx Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-41.18

-119.16

-57.66

-30.19

-6.31

Ardelyx Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-41.19	-33.60	-16.30	6.15	13.20

Ardelyx ROCE % Calculation

Ardelyx's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-17.931	/	( ( (272.88 - 46.21)	+	(416.145 - 74.328) )	/ 2 )
	=	-17.931	/	( (226.67	+	341.817)	/ 2 )
	=	-17.931	/	284.2435
	=	-6.31 %

Ardelyx's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	40.236	/	( ( (331.445 - 63.52)	+	(416.145 - 74.328) )	/ 2 )
	=	40.236	/	( ( 267.925	+	341.817 )	/ 2 )
	=	40.236	/	304.871
	=	13.20 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Ardelyx (FRA:41X) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Ardelyx ROCE % Related Terms

Thank you for viewing the detailed overview of Ardelyx's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ardelyx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ardelyx Inc (FRA:41X) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ARDX:USA

Address

400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451

Website

https://www.ardelyx.com

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Ardelyx Headlines

No Headlines